Regulus Therapeutics Inc. (RGLS)

Develops microRNA-based therapeutics for metabolic, fibrotic, and orphan diseases.

RGLS Stock Quote

Company Report

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering the discovery and development of therapeutics that specifically target microRNAs to address a spectrum of diseases within the United States. At the forefront of its innovative portfolio are promising product candidates such as RG-012, an anti-miR designed to inhibit miR-21, currently undergoing Phase II clinical trials for the treatment of Alport syndrome a severe kidney disease with life-threatening implications.

Additionally, Regulus Therapeutics is advancing RGLS8429, another anti-miR targeting miR-17, currently in Phase 1b clinical studies aimed at treating autosomal dominant polycystic kidney disease, a genetic disorder characterized by cyst formation in the kidneys. Complementing its clinical efforts, the company is actively developing a pipeline of preclinical drug products that employ innovative strategies for organ-selective delivery.

Founded in 2007 and headquartered in San Diego, California, Regulus Therapeutics continues to push the boundaries of biopharmaceutical innovation. With a strategic focus on microRNA-based therapies, the company remains committed to advancing treatments that have the potential to transform the lives of patients facing complex and challenging medical conditions.

RGLS EPS Chart

RGLS Revenue Chart

Stock Research

GL CNHI AURA SMBC NVST CPSS QUIK

RGLS Chart

View interactive chart for RGLS

RGLS Profile

RGLS News

Analyst Ratings